Top > Search of International Patents > IgG binding peptide

IgG binding peptide

Foreign code F130007492
Posted date Jul 10, 2013
Country United States of America
Application number 31226807
Gazette No. 20100297606
Gazette No. 8372950
Date of filing Nov 2, 2007
Gazette Date Nov 25, 2010
Gazette Date Feb 12, 2013
International application number JP2007071754
International publication number WO2008054030
Date of international filing Nov 2, 2007
Date of international publication May 8, 2008
Priority data
  • P2006-299566 (Nov 2, 2006) JP
  • 2007WO-JP71754 (Nov 2, 2007) WO
Title IgG binding peptide
Abstract (US8372950)
The present invention provides a peptide capable of specifically binding to human IgG.
In particular, the present invention relates to a human IgG binding peptide tag of 11 to 16 amino acids in length, comprising at least an amino acid sequence of the formula I: C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17) wherein n and m are each an integer of 1 or more and the sum n+m is 4 or 5, wherein X-X-X in the formula I contains no cysteine residue, and wherein said amino acid sequence satisfies either or both of a) and b): a) (X)n-W in the formula I denotes Za-G-Y-W (SEQ ID NO: 18); and b) W-(X)m in the formula I denotes W-G-L-Zb (SEQ ID NO: 19) wherein Za and Zb are each 0, 1, or more amino acid residues.
Scope of claims [claim1]
1. A human IgG binding peptide tag that is 11 to 16 amino acids in length, comprising at least an amino acid sequence of formula I:
C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17)
wherein n and m are each an integer of 1 or more and the sum n+m is 4 or 5, wherein X-X-X in the formula I contains no cysteine residue, and
wherein said amino acid sequence satisfies either or both of a) and b): a) (X)n-W in the formula I is Za-G-Y-W (SEQ ID NO: 18); and
b) W-(X)m in the formula I is W-G-L-Zb (SEQ ID NO: 19)
wherein Za and Zb are each 0, 1, or more amino acid residues.
[claim2]
2. The peptide tag according to claim 1, wherein said amino acid sequence of the formula I satisfies both a) and b): a) (X)n-W in the formula I is Za-G-Y-W (SEQ ID NO: 18); and
b) W-(X)m in the formula I is W-G-L-Zb (SEQ ID NO: 19)
wherein Za and Zb are each 0, 1, or more amino acid residues.
[claim3]
3. The peptide tag according to claim 1, which consists of any of the amino acid sequences 1) to 11):
1) CGYWRSEWGLC;(SEQ ID NO: 1) 2) CTGFWEREWGLC;(SEQ ID NO: 2) 3) CLYWPRLWGLC;(SEQ ID NO: 3) 4) CTGYWPKAWGLC;(SEQ ID NO: 4) 5) CYWAVRWGLLGC;(SEQ ID NO: 5) 6) CGYWADVWQIHC;(SEQ ID NO: 6) 7) GCGYWRSEWGLCG;(SEQ ID NO: 7) 8) GCTGFWEREWGLCG;(SEQ ID NO: 8) 9) GCTGYWPKAWGLCG;(SEQ ID NO: 9)10) GCGYWRSQWGLCG;(SEQ ID NO: 10)and11) GCTGYWPRAWGLCG(SEQ ID NO: 11).
[claim4]
3. The peptide tag according to
-- 1) CGYWRSEWGLC; (SEQ ID NO: 1)
--
-- 2) CTGFWEREWGLC; (SEQ ID NO: 2)
--
-- 3) CLYWPRLWGLC; (SEQ ID NO: 3)
--
-- 4) CTGYWPKAWGLC; (SEQ ID NO: 4)
--
-- 5) CYWAVRWGLLGC; (SEQ ID NO: 5)
--
-- 6) CGYWADVWQIHC; (SEQ ID NO: 6)
--
-- 7) GCGYWRSEWGLCG; (SEQ ID NO: 7)
--
-- 8) GCTGFWEREWGLCG; (SEQ ID NO: 8)
--
-- 9) GCTGYWPKAWGLCG; (SEQ ID NO: 9)
--
-- 10) GCGYWRSQWGLCG; (SEQ ID NO: 10)
-- and
--
-- 11) GCTGYWPRAWGLCG (SEQ ID NO: 11).
[claim5]
4. The peptide tag according to any claim 1, wherein a disulfide bond is formed between two cysteine residues in formula I.
[claim6]
5. The peptide tag according to claim 1, which binds to acid-denatured human IgG.
[claim7]
6. A human IgG binding peptide tag that is 11 to 16 amino acids in length, comprising at least an amino acid sequence of formula I:
-- C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17)
[claim8]
7. A fusion protein of the following formula: P1-C-(X)n-W-X-X-X-W-(X)m-C-P2
wherein
C-(X)n-W-X-X-X-W-(X)m-C(I)(SEQ ID NO: 17)
is a human IgG binding peptide tag that is 11 to 16 amino acids in length,
wherein n and m are each an integer of 1 or more and the sum n+m is 4 or 5, wherein X-X-X in the formula contains no cysteine residue, and
wherein said human IgG binding peptide tag satisfies either or both of a) and b): a) (X)n-W in the formula is Za-G-Y-W (SEQ ID NO: 18); and
b) W-(X)m in the formula is W-G-L-Zb (SEQ ID NO: 19)
wherein Za and Zb are each 0, 1, or more amino acid residues,
wherein either of P1 and P2 is present, but P1 and P2 are not both present at the same time,
wherein P1, when present, is bonded to the N-terminus of the human IgG binding peptide tag C-(X)n-W-X-X-X-W-(X)m-C (SEQ ID NO:17),
wherein P2, when present, is bonded to the C-terminus of the human IgG binding peptide tag C-(X)n-W-X-X-X-W-(X)m-C (SEQ ID NO:17),
and wherein P1 and P2 each represents a protein.
[claim9]
7. A fusion protein of the following formula:
-- C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17)
[claim10]
8. A solid phase support, on which the peptide tag according to claim 1 is immobilized.
[claim11]
9. A method for determining the presence of human IgG or an Fc region-containing fragment thereof in a sample, comprising the steps a) to c): a) contacting a sample with acid to produce an acid-treated sample;
b) contacting the acid-treated sample with the peptide tag according to claim 1; and
c) measuring a binding affinity produced in the step b) between the peptide tag and human IgG or an Fc region-containing fragment thereof, wherein the binding affinity having a dissociation constant of 0.1 nM to 50 nM indicates the presence of human IgG or an Fc region-containing fragment thereof in a sample.
[claim12]
10. The method according to claim 9, wherein the binding affinity is measured by surface plasmon resonance analysis.
[claim13]
11. A method for purifying human IgG or an Fc region-containing fragment thereof in a sample, comprising the steps a) and b): a) contacting the peptide tag according to claim 1 with an acid-treated sample containing human IgG or an Fc region-containing fragment thereof, thereby binding human IgG or an Fc region-containing fragment thereof in the sample to the peptide tag; and
b) separating the human IgG or the Fc region-containing fragment thereof, which is bound to the peptide tag in the step a), from the sample.
[claim14]
12. A method for removing an acid-denatured human IgG or Fc region-containing fragment thereof from a sample, comprising the steps a) and b): a) contacting the peptide tag according to claim 1 with a sample containing acid-denatured human IgG or an Fc region-containing fragment thereof; and
b) removing human IgG or an Fc region-containing fragment thereof bound to the peptide tag prepared by the step a), from the sample.
[claim15]
13. A method for purifying a protein, comprising the steps a) to c): a) producing a fusion protein according to claim 7, and then preparing a sample containing the fusion protein;
b) contacting the sample prepared by step a) with acid-treated human IgG or an Fc region-containing fragment thereof, thereby binding the fusion protein to the human IgG or Fc region-containing fragment thereof; and
c) separating the fusion protein, which is bound to the human IgG or Fc region-containing fragment thereof in the step b), from the sample.
  • Inventor, and Inventor/Applicant
  • ITO YUJI
  • KAGOSHIMA UNIVERSITY
IPC(International Patent Classification)
U.S. Cl./(Sub)
  • C07K001/22
  • C07K007/06
  • C07K007/08
  • G01N033/68B2
  • G01N033/68B
Please contact us by E-mail if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close